

Supplementary Table S1. Comparison of clinical and molecular characteristics between the two groups of Gentuzumab ozogamicin (GO) treatment.

Characteristic	NO-GO treatment (n=95)	GO treatment (n=158)	P-value
Age/years, median (range)	10.7(0.1-23.5)	10.4(0.4-22.5)	0.840*
Age group/n (%)			0.709§
<10 years	44(46.3)	77(48.7)	
≥10 years	51(53.7)	81(51.3)	
Gender/n (%)			0.303§
Male	49(51.6)	92(58.2)	
Female	46(48.4)	66(41.8)	
Ethnicity/n(%)			
Hispanic or Latino	21(22.1)	30(19)	0.549§
Not Hispanic or Latino	68(71.6)	124(78.5)	0.214§
Unknown	6(6.3)	4(2.5)	0.135§
WBC/×10⁹/L, median (range)	33.5(0.9-519)	52.85(1.5-446)	0.217*
BM blast/%, median (range)	71(20-99)	77(21-100)	0.101*
PB blast/%, median (range)	63(0-97)	61(0-97)	0.969*
FAB subtypes/n (%)			
M0	2(2.1)	6(3.8)	0.456§
M1	13(13.7)	19(12)	0.700§
M2	23(24.2)	34(21.5)	0.619§
M4	14(14.7)	43(27.2)	0.021§
M5	16(16.8)	32(20.3)	0.503§
M6	1(1.1)	2(1.3)	0.879§
M7	6(6.3)	2(1.3)	0.026§

Others	20(21.1)	20(12.7)	0.076 [§]
Cytogenetics/n (%)			
Normal	20(21.1)	45(28.5)	0.190 [§]
Complex karyotype	14(14.7)	23(14.6)	0.969 [§]
<i>inv(16)/CBFβ-MYH11</i>	12(12.6)	24(15.2)	0.573 [§]
<i>11q23/MLL</i>	18(18.9)	23(14.6)	0.359 [§]
<i>t(8;21)/RUNX1-RUNX1T1</i>	17(17.9)	21(13.3)	0.321 [§]
Others	14(14.7)	22(13.9)	0.858 [§]
Risk/n (%)			
Good	39(41.1)	64(40.5)	0.932 [§]
Intermediate	46(48.4)	69(43.7)	0.462 [§]
Poor	10(10.5)	17(10.8)	0.954 [§]
Others	0(0)	8(5.1)	0.026 [§]
<i>FLT3-ITD</i>/n (%)			0.204 [§]
Positive	19(20)	22(13.9)	
Negative	76(80)	136(86.1)	
<i>NPM1</i>/n (%)			0.600 [§]
Mutation	9(9.5)	12(7.6)	
Wild type	86(90.5)	146(92.4)	
<i>CEBPA</i>/n (%)			0.591 [§]
Mutation	5(5.3)	11(7)	
Wild type	90(94.7)	147(93)	
<i>WT1</i>/n (%)			0.733 [§]
Mutation	9(9.5)	13(8.2)	
Wild type	86(90.5)	145(91.8)	

c-Kit Mutation Exon 8/n (%)

Yes	6(6.3)	8(5.1)	0.673 [§]
No	23(24.2)	30(19)	0.323 [§]
Not done	66(69.5)	120(75.9)	0.258 [§]

c-Kit Mutation Exon 17/n (%)

Yes	7(7.4)	7(4.4)	0.322 [§]
No	22(23.2)	31(19.6)	0.503 [§]
Not done	66(69.5)	120(75.9)	0.258 [§]

CNS disease/n (%)

Yes	3(3.2)	12(7.6)	0.148 [§]
No	92(96.8)	146(92.4)	

Abbreviations: WBC, white blood cell; BM, bone marrow; PB, peripheral blood; FAB, French American British; CNS, Central Nervous System;

‘*’ denotes Mann-Whitney U test; ‘§’ denotes chi-square test. Complex karyotype is defined as more than or equal to 3 chromosomal abnormalities.